SCHEMBL155111

SCHEMBL155111

Brc1ccc2c(c1)CCO2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.53
BLM P54132 1/20 0.53
PRKCI P41743 1/20 0.52
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
DYRK1A Q13627 3/20 0.47
DYRK2 Q92630 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
RAB9A P51151 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29584634 1.00 MAPT (0.53) MAPTLMNAHTTBLMPRKCI
SCHEMBL7839082 0.98 MAPT (0.52) MAPTLMNAHTTBLMPRKCI
SCHEMBL4854354 0.88 LMNA (0.50) MAPTLMNAHTTBLMPRKCI
SCHEMBL3520162 0.86 LMNA (0.48) MAPTLMNAHTTBLMPRKCI
SCHEMBL267355 0.83 LMNA (0.53) MAPTLMNAHTTBLMPRKCI
SCHEMBL30640621 0.80 DYRK1A (0.54) MAPTPRKCIDYRK1ADYRK2DYRK1B
SCHEMBL8187712 0.80 DYRK1A (0.54) MAPTPRKCIDYRK1ADYRK2DYRK1B
SCHEMBL2177890 0.79 LMNA (0.41) MAPTLMNAHTTBLMPRKCI
SCHEMBL23188919 0.79 DYRK1A (0.40) MAPTLMNAHTTBLMPRKCI
SCHEMBL6587136 0.79 DYRK1A (0.46) MAPTLMNAHTTBLMPRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110452201-B Synthetic method of benzofuran heterocyclic sulfonyl chloride 泰州职业技术学院 2022-09-23 CN claimed
CN-104370865-A Method for synthesizing 3-(2,3-dihydrobenzofuran-5-yl) propionic acid through Heck reaction SUZHOU JONATHAN NEW MATERIALS TECHNOLOGY CO LTD 2015-02-25 CN claimed
CN-101279963-A Preparation of darifenacin intermediate 5-(halogenated ethyl)-2,3-dihydrobenzofuran BEIJING CHEMSUN PHARMACEUTICAL (CN) 2008-10-08 CN claimed
EP-4720037-A1 CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF 16380026 Canada Inc. (CA) 2026-04-08 EP disclosed
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
EP-4694889-A1 COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES Acelot, Inc. (US) 2026-02-18 EP disclosed
EP-4626870-A1 NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS University of Copenhagen (DK) 2025-10-08 EP disclosed
US-12398097-B2 WDR5-MYC inhibitors VANDERBILT UNIVERSITY (US) 2025-08-26 US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 US disclosed
EP-4584259-A1 CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS Innovo Therapeutics, Inc. (US) 2025-07-16 EP disclosed
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND SHOUYAO HOLDINGS BEIJING CO LTD (CN) 2025-07-10 US disclosed
US-6043247-A A SUBSTITUTED ACRYLIC ACIDS FOR USE IN TREATMENT OF HUMAN AND ANIMAL DISORDERS, AND PURIFICATION OF PROTEINS OR GLYCOPROTEINS, AND TO THEIR USE IN DIAGNOSIS NOVO NORDISK A/S (DK) 2000-03-28 US disclosed
WO-1999043657-A1 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 1999-09-02 WO disclosed
WO-1997039748-A1 MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS NOVO NORDISK A/S (DK) 1997-10-30 WO disclosed
EP-0482108-B1 SUBSTITUTED 2-IMIDAZOLINES AND PREPARATION AND USE THEREOF NOVO NORDISK AS (DK) 1996-03-20 EP disclosed
US-5340833-A Antiarthritic, antiinflammatory, antitumor agents EISAI CO., LTD. (JP) 1994-08-23 US disclosed
US-5262430-A Antidiabetic agent lowers blood glucose in mammals in type 2 non insulin dependent diabetes NOVO NORDISK A/S (DK) 1993-11-16 US disclosed
EP-0568289-A2 Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors Eisai Co., Ltd. (JP) 1993-11-03 EP disclosed
EP-0482108-A1 SUBSTITUTED 2-IMIDAZOLINES AND PREPARATION AND USE THEREOF. NOVO NORDISK AS (DK) 1992-04-29 EP disclosed
WO-1991000862-A1 SUBSTITUTED 2-IMIDAZOLINES AND PREPARATION AND USE THEREOF NOVO NORDISK A/S (DK) 1991-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B MAPT 2629/4885LMNA 3274/4885HTT 941/4885
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND MAPT, MNAT1, MAT2A MAPT 1/4885LMNA 876/4885HTT 17/4885
US-12398097-B2 WDR5-MYC inhibitors MYC, WDR5, MYCBP MAPT 1222/4885LMNA 2680/4885HTT 1364/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 MAPT 1136/4885LMNA 1392/4885HTT 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.